m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

[1]  Xiao-jun Huang,et al.  The role of m6A demethylase FTO in chemotherapy resistance mediating acute myeloid leukemia relapse , 2023, Cell death discovery.

[2]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[3]  Xiao‐Yu Yin,et al.  Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Yihang Yu,et al.  MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro , 2022, Cells.

[5]  Baochi Ou,et al.  Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m6A demethylation , 2022, Cell Death & Disease.

[6]  Guohui Wan,et al.  N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  A. Goel,et al.  Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma , 2022, Pharmaceuticals.

[8]  Lianfang Zheng,et al.  HIF‐1α‐regulated stanniocalcin‐1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway , 2022, Molecular carcinogenesis.

[9]  Jiali Yang,et al.  Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer , 2022, Molecular cancer.

[10]  Weiqi Wang,et al.  RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner , 2022, Oncogene.

[11]  Chunze Zhang,et al.  FTO promotes colorectal cancer progression and chemotherapy resistance via demethylating G6PD/PARP1 , 2022, Clinical and translational medicine.

[12]  A. Loguinov,et al.  Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 , 2021, Molecular Cancer Therapeutics.

[13]  Fan Wang,et al.  LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway , 2021, Cancer Research.

[14]  W. Wang,et al.  A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression , 2021, Cancer Research.

[15]  B. Erickson,et al.  Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac , 2021, Acta oncologica.

[16]  C. Tisné,et al.  A comprehensive review of m6A/m6Am RNA methyltransferase structures , 2021, Nucleic acids research.

[17]  Yongyan Wu,et al.  Regulatory role and mechanism of m6A RNA modification in human metabolic diseases , 2021, Molecular therapy oncolytics.

[18]  Q. Lan,et al.  The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance , 2021, Cancer Research.

[19]  Cuiping Yang,et al.  The role of m6A modification in the biological functions and diseases , 2021, Signal Transduction and Targeted Therapy.

[20]  Yan Wang,et al.  Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin , 2021, Bioengineered.

[21]  Schraga Schwartz,et al.  The epitranscriptome beyond m6A , 2020, Nature Reviews Genetics.

[22]  D. Saur,et al.  Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component , 2020, bioRxiv.

[23]  Zhou Wang,et al.  Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance , 2020, Investigational New Drugs.

[24]  Yun Feng,et al.  RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner , 2020, Molecular Cancer.

[25]  S. Ju,et al.  The potential role of RNA N6-methyladenosine in Cancer progression , 2020, Molecular Cancer.

[26]  W. Xie,et al.  m6A-binding proteins: the emerging crucial performers in epigenetics , 2020, Journal of Hematology & Oncology.

[27]  E. Hirsch,et al.  PI(3,4)P2 Signaling in Cancer and Metabolism , 2020, Frontiers in Oncology.

[28]  Weifeng Hong,et al.  Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival , 2020, Annals of translational medicine.

[29]  Z. Qiu,et al.  Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. , 2020, Oncology letters.

[30]  Dewei Wang,et al.  Abnormality of m6A mRNA Methylation Is Involved in Alzheimer’s Disease , 2020, Frontiers in Neuroscience.

[31]  F. Shimamoto,et al.  m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling , 2020, Molecular Cancer.

[32]  Y. Miao,et al.  The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. , 2019, Pathology, research and practice.

[33]  C. Pilarsky,et al.  Chemoresistance in Pancreatic Cancer , 2019, International journal of molecular sciences.

[34]  G. Mills,et al.  Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation , 2019, Breast Cancer Research.

[35]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[36]  E. Hirsch,et al.  Class II PI3K Functions in Cell Biology and Disease. , 2019, Trends in cell biology.

[37]  I. Bezsonova,et al.  USP7: Structure, substrate specificity, and inhibition. , 2019, DNA repair.

[38]  Min Gyu Lee,et al.  PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression , 2019, Nature Communications.

[39]  Sicong Zhang.  Mechanism of N6-methyladenosine modification and its emerging role in cancer. , 2018, Pharmacology & therapeutics.

[40]  R. Hajjar,et al.  FTO-Dependent N6-Methyladenosine Regulates Cardiac Function During Remodeling and Repair , 2018, Circulation.

[41]  S. Naderi,et al.  MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent. , 2018, Atherosclerosis.

[42]  M. Ghosh,et al.  Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases , 2018, Signal Transduction and Targeted Therapy.

[43]  T. Yokobori,et al.  Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model. , 2017, Oncology letters.

[44]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[45]  Jianguo Sun,et al.  Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non–small-cell lung cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[46]  Amjad Ali,et al.  USP7 deubiquitinase controls HIV-1 production by stabilizing Tat protein. , 2017, The Biochemical journal.

[47]  Haidi Yang,et al.  NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells , 2017, Cell cycle.

[48]  K. Olive,et al.  Current and Emerging Therapies in Metastatic Pancreatic Cancer , 2017, Clinical Cancer Research.

[49]  S. Lakhani,et al.  DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer , 2017, Oncogene.

[50]  J. Cameron,et al.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.

[51]  Q. Fu,et al.  miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR–p-PI3K/AKT-c-JUN , 2016, Nature Communications.

[52]  T. Conroy,et al.  Current standards and new innovative approaches for treatment of pancreatic cancer. , 2016, European journal of cancer.

[53]  S. Na'ara,et al.  Gemcitabine resistance in pancreatic ductal adenocarcinoma. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[54]  W. Duan,et al.  Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. , 2014, Cancer letters.

[55]  D. Iliopoulos,et al.  MicroRNA-gene signaling pathways in pancreatic cancer. , 2013, Biomedical journal.

[56]  Simon Hess,et al.  The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry , 2013, Nature Neuroscience.

[57]  Gideon Rechavi,et al.  Transcriptome-wide mapping of N6-methyladenosine by m6A-seq based on immunocapturing and massively parallel sequencing , 2013, Nature Protocols.

[58]  Rugang Zhang,et al.  Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. , 2011, Molecular cell.

[59]  Malte Buchholz,et al.  Stromal biology and therapy in pancreatic cancer , 2010, Gut.

[60]  Roger D. Cox,et al.  Overexpression of Fto leads to increased food intake and results in obesity , 2010, Nature Genetics.

[61]  J. Schellens,et al.  Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. , 2008, The oncologist.

[62]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[63]  D. Liu,et al.  The HAUSP gene plays an important role in non‐small cell lung carcinogenesis through p53‐dependent pathways , 2006, The Journal of pathology.

[64]  K. Jauch,et al.  Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[65]  M. Khaled,et al.  PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes , 2004, Cell Death and Differentiation.

[66]  Godefridus J Peters,et al.  Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[67]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Y Z Xu,et al.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.

[69]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[70]  G. Moore,et al.  Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma , 1980, International journal of cancer.

[71]  Sarfraz Ahmad,et al.  Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer. , 2019, Critical reviews in oncogenesis.

[72]  Wei Huang,et al.  Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5. , 2015, The Journal of clinical endocrinology and metabolism.

[73]  V. Speirs,et al.  The potential utility of geminin as a predictive biomarker in breast cancer , 2013, Breast Cancer Research and Treatment.

[74]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[75]  G. Peters,et al.  Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors , 1996, Cancer Chemotherapy and Pharmacology.